Supernus Pharmaceuticals SUPN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $207.71M-1.8% | $211.57M+10.1% | $192.1M+16.1% | $165.45M+10.4% | $149.82M-14.0% | ||
| $23.39M+1.7% | $23.01M+21.3% | $18.97M+12.7% | $16.83M+6.7% | $15.76M-39.6% | ||
| $184.31M-2.3% | $188.57M+8.9% | $173.14M+16.5% | $148.63M+10.9% | $134.06M-9.5% | ||
| 88.7%-0.4pp | 89.1%-1.0pp | 90.1%+0.3pp | 89.8%+0.4pp | 89.5%+4.5pp | ||
| $39.44M+41.7% | $27.83M-5.2% | $29.37M+32.8% | $22.12M-17.9% | $26.93M-6.0% | ||
| $125.17M+2.3% | $122.39M-31.9% | $179.68M+92.1% | $93.55M+4.0% | $89.94M+13.3% | ||
| $8.48M— | —— | —— | —— | $8.07M— | ||
| $27.4M— | —— | —— | —— | $26.1M— | ||
| $26.13M+6.5% | $24.53M+0.8% | $24.33M+16.8% | $20.82M+2.1% | $20.38M+11.7% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $216.04M+0.2% | $215.51M-14.6% | $252.33M+64.6% | $153.31M-4.2% | $160.08M+4.8% | ||
| -$8.33M-112% | -$3.94M+93.5% | -$60.23M-596% | $12.14M+218% | -$10.26M-148% | ||
| -4%-2.2pp | -1.9%+29.5pp | -31.4%-38.7pp | 7.3%+14.2pp | -6.8%-19.1pp | ||
| $2.38M+17.7% | $2.02M-11.2% | $2.28M-49.7% | $4.53M+2.3% | $4.43M-11.1% | ||
| $21K— | —— | —— | —— | -$9K— | ||
| -$5.95M-211% | -$1.91M+96.7% | -$57.95M-448% | $16.67M+386% | -$5.83M-122% | ||
| -$3.66M— | —— | -$12.84M-120% | -$5.83M-197% | $6M-45.8% | ||
| -$2.29M+44.1% | -$4.11M+90.9% | -$45.12M-301% | $22.5M+290% | -$11.83M-177% | ||
| -1.1%+0.8pp | -1.9%+21.5pp | -23.5%-37.1pp | 13.6%+21.5pp | -7.9%-16.7pp | ||
| -$0.04+42.9% | -$0.07+91.3% | -$0.80-300% | $0.40+290% | -$0.21-178% | ||
| -$0.04+42.9% | -$0.07+91.3% | -$0.80-300% | $0.40+290% | -$0.21-175% | ||
| 57.6M+2.1% | 56.5M-0.2% | 56.6M-0.2% | 56.6M+1.4% | 55.9M-0.2% | ||
| 57.6M+2.1% | 56.5M-0.2% | 56.6M+0.9% | 56M+0.3% | 55.9M+1.4% | ||
| $8.48M— | —— | —— | —— | $8.07M— | ||
| $27.4M— | —— | —— | —— | $26.1M— | ||
| $8.48M— | —— | —— | —— | $8.07M— | ||
| $25.64M+4.6% | $24.53M+0.8% | $24.33M+16.8% | $20.82M+5.2% | $19.79M+8.5% | ||
| $2.39M-86.5% | $17.76M— | $0— | $0-100% | $7.66M— | ||
| $56.42M— | —— | —— | —— | $46.52M— | ||
| -$2.5M— | —— | —— | —— | -$11.8M— | ||
| -1%— | —— | —— | —— | -5%— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $21K— | —— | —— | —— | -$9K-500% | ||
| $5.92M-68.9% | $19M+818% | -$2.65M+63.1% | -$7.16M-79.5% | -$3.99M-5,442% | ||
| $0.62— | —— | —— | —— | -$1.03— | ||
| -$2.39M— | —— | —— | —— | -$7.66M— | ||
| $0— | —— | —— | —— | $25M— | ||
| $33.44M— | —— | —— | —— | —— | ||
| -$4.21M-314% | $1.97M0.0% | $1.97M0.0% | $1.97M0.0% | $1.97M— | ||
| -$412K-252% | $271K-91.2% | $3.08M-75.2% | $12.42M+4,434% | $274K-97.9% | ||
| $49K+110% | -$491K+97.7% | -$21.53M-232% | -$6.49M-265% | $3.94M+1,042% | ||
| -$5.62M-134% | $16.42M+130% | $7.13M+248% | -$4.81M-235% | $3.56M+207% | ||
| $28.62M— | —— | —— | —— | $1.43M— | ||
| $105K-97.5% | $4.18M-67.7% | $12.94M+365% | -$4.89M-3.3% | -$4.73M-48.4% | ||
| $12.43M+80.0% | $6.91M-38.0% | $11.14M+345% | $2.5M+134% | -$7.37M-168% | ||
| $0— | —— | —— | —— | $0— | ||
| $1.5M— | —— | —— | —— | $4.4M— | ||
| $1.82M— | —— | —— | —— | $547K— | ||
| $192K— | —— | —— | —— | $1.07M— | ||
| $9.12M+6.9% | $8.53M-59.5% | $21.07M+2,153% | $935K+104% | -$21.4M-463% | ||
| -$19.22M— | —— | $48.71M— | —— | $37.32M+395% | ||
| $66.52M+235% | $19.86M— | —— | $58.54M+91.3% | $30.6M-31.1% | ||
| 9— | —— | —— | —— | —— | ||
| 1— | —— | —— | —— | —— | ||
| 1— | —— | —— | —— | —— | ||
| $2.26M— | —— | —— | —— | $1.34M-1.6% | ||
| -$211K— | —— | —— | —— | $30K— | ||
| -$211K— | —— | —— | —— | $30K— | ||
| -$284K— | —— | -$3.83M-15.9% | -$3.3M-594% | -$476K— | ||
| $2.38M+17.7% | $2.02M-11.2% | $2.28M-49.7% | $4.53M+2.3% | $4.43M-11.1% | ||
| $0— | $0-100% | $1.86M-18.9% | $2.3M-88.6% | $20.1M— | ||
| $0— | —— | —— | —— | $4.9M— | ||
| $4.56M+14,594% | $31K-96.2% | $811K+1,663% | $46K-98.6% | $3.34M+239% | ||
| $78.44M-13.0% | $90.2M-28.8% | $126.63M-9.9% | $140.56M+18.6% | $118.56M-18.5% | ||
| $0-100% | $427K+231% | $129K-71.6% | $455K+39.1% | $327K+53.5% | ||
| $13.67M+59.8% | $8.56M-64.0% | $23.74M+625% | $3.28M+60.4% | $2.04M-70.3% | ||
| $59.22M+50.6% | $39.32M-91.6% | $468.56M+324% | $110.4M-29.3% | $156.2M+17.5% | ||
| 50%— | —— | —— | —— | —— | ||
| $207.71M-1.8% | $211.57M+10.1% | $192.1M+16.1% | $165.45M+10.4% | $149.82M-14.0% | ||
| $8.48M-12.1% | $9.65M+23.3% | $7.83M+4.2% | $7.51M-7.0% | $8.07M+5.7% | ||
| 892.4K— | —— | —— | —— | —— | ||
| 19.5K— | —— | —— | —— | —— | ||
| $39.90— | —— | —— | —— | —— | ||
| $50.20— | —— | —— | —— | —— | ||
| $30.83— | —— | —— | —— | —— | ||
| 443.4K— | —— | —— | —— | —— | ||
| $9.12M— | —— | —— | —— | -$1.3M— | ||
| -$8.33M-112% | -$3.94M+93.5% | -$60.23M-596% | $12.14M+218% | -$10.26M-148% | ||
| $17.8M-15.6% | $21.08M+160% | -$35.43M-206% | $33.5M+231% | $10.13M-74.8% | ||
| $17.8M-15.6% | $21.08M+160% | -$35.43M-206% | $33.5M+231% | $10.13M-74.8% | ||
| 8.6%-1.4pp | 10%+28.4pp | -18.4%-38.7pp | 20.2%+13.5pp | 6.8%-16.4pp | ||
| -$8.33M-112% | -$3.94M+93.5% | -$60.23M-596% | $12.14M+218% | -$10.26M-148% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Supernus Pharmaceuticals's profit margins?
- Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
- Where does Supernus Pharmaceuticals's income statement data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.